Cidara Therapeutics Inc. (CDTX)
Cidara Therapeutics Statistics
Share Statistics
Cidara Therapeutics has 10.95M shares outstanding. The number of shares has increased by -92.22% in one year.
| Shares Outstanding | 10.95M |
| Shares Change (YoY) | -92.22% |
| Shares Change (QoQ) | 0.12% |
| Owned by Institutions (%) | 0.09% |
| Shares Floating | 6.84M |
| Failed to Deliver (FTD) Shares | 2.37K |
| FTD / Avg. Volume | 1.87% |
Short Selling Information
The latest short interest is 66.98K, so 0.61% of the outstanding shares have been sold short.
| Short Interest | 66.98K |
| Short % of Shares Out | 0.61% |
| Short % of Float | 1.44% |
| Short Ratio (days to cover) | 3.88 |
Valuation Ratios
The PE ratio is -1.01 and the forward PE ratio is -2.21. Cidara Therapeutics's PEG ratio is 0.
| PE Ratio | -1.01 |
| Forward PE | -2.21 |
| PS Ratio | 133.87 |
| Forward PS | 1.6 |
| PB Ratio | 1.05 |
| P/FCF Ratio | -0.97 |
| PEG Ratio | 0 |
Enterprise Valuation
Cidara Therapeutics Inc. has an Enterprise Value (EV) of 1.36B.
| EV / Earnings | -7.99 |
| EV / Sales | 1064.66 |
| EV / EBITDA | -7.71 |
| EV / EBIT | -7.71 |
| EV / FCF | -7.68 |
Financial Position
The company has a current ratio of 4.25, with a Debt / Equity ratio of 0.02.
| Current Ratio | 4.25 |
| Quick Ratio | 4.25 |
| Debt / Equity | 0.02 |
| Total Debt / Capitalization | 2.14 |
| Cash Flow / Debt | -49.37 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.04% and return on capital (ROIC) is -105.52%.
| Return on Equity (ROE) | -1.04% |
| Return on Assets (ROA) | -0.79% |
| Return on Capital (ROIC) | -105.52% |
| Revenue Per Employee | $33,552.63 |
| Profits Per Employee | $-4,469,131.58 |
| Employee Count | 38 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 22.07% in the last 52 weeks. The beta is 0.88, so Cidara Therapeutics's price volatility has been higher than the market average.
| Beta | 0.88 |
| 52-Week Price Change | 22.07% |
| 50-Day Moving Average | 21.84 |
| 200-Day Moving Average | 16.4 |
| Relative Strength Index (RSI) | 50.16 |
| Average Volume (20 Days) | 126.67K |
Income Statement
In the last 12 months, Cidara Therapeutics had revenue of 1.27M and earned -169.83M in profits. Earnings per share was -26.82.
| Revenue | 1.27M |
| Gross Profit | -83.61M |
| Operating Income | -176.1M |
| Net Income | -169.83M |
| EBITDA | -176.1M |
| EBIT | -176.1M |
| Earnings Per Share (EPS) | -26.82 |
Balance Sheet
The company has 189.82M in cash and 3.58M in debt, giving a net cash position of 186.25M.
| Cash & Cash Equivalents | 189.82M |
| Total Debt | 3.58M |
| Net Cash | 186.25M |
| Retained Earnings | -611.26M |
| Total Assets | 214.8M |
| Working Capital | 161.18M |
Cash Flow
In the last 12 months, operating cash flow was -176.53M and capital expenditures -129K, giving a free cash flow of -176.66M.
| Operating Cash Flow | -176.53M |
| Capital Expenditures | -129K |
| Free Cash Flow | -176.66M |
| FCF Per Share | -27.82 |
Margins
Gross margin is -6.56K%, with operating and profit margins of -13.81K% and -13.32K%.
| Gross Margin | -6.56K% |
| Operating Margin | -13.81K% |
| Pretax Margin | -13.36K% |
| Profit Margin | -13.32K% |
| EBITDA Margin | -13.81K% |
| EBIT Margin | -13.81K% |
| FCF Margin | -13.86K% |
Dividends & Yields
CDTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -119.41% |
| FCF Yield | -71.81% |
Analyst Forecast
The average price target for CDTX is $35, which is 55.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $35 |
| Price Target Difference | 55.8% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Stock Splits
The last stock split was on Apr 24, 2024. It was a backward split with a ratio of 1:20.
| Last Split Date | Apr 24, 2024 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | -1.72 |
| Piotroski F-Score | 1 |